Multiple Sclerosis Drugs Market By Product Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Multiple Sclerosis Drugs Market
Multiple Sclerosis Drugs Market: By Product Type (Immunomodulators, Immunosuppressant, Others), By Administration (Inject able, Infused, Oral), & By Geography (Europe, Asia Pacific, North America, Rest of the World)-Forecast (2016-2021)
Report Code : HCR 0322
Published On: 08 March, 2016   Updated On: 08 March, 2016

  • Report Description
  • Table of Contents
  • Customization Options
Multiple sclerosis (MS) is a nervous system disease which affects spinal cord and the brain. MS damages the myelin sheath. Myelin sheath is a term which exemplifies that material which surrounds and protects human nerve cells. Globally, high Unmet need of drugs for treatment of the disease, increased research in the field of MS to develop innovative therapies  are the prime growth drivers of global Musculoskeletal Diseases market. In addition, increase in adoption of Multiple Sclerosis Drugs in emerging economies such as China, India and others, will create new opportunities for global Multiple Sclerosis Drugs market. However, patent expiry of major drugs and advancement in biomedical science are the key restraints for global Musculoskeletal Diseases market.

Multiple Sclerosis Drugs Market

Geographically North America dominated global Multiple Sclerosis Drugs market, The U.S. represents the largest market for MS drugs followed by Canada in North America. In Europe, France, Germany, Italy, Spain and the U.K. holds major share of MS drugs market. However, Asia is expected to show high growth rates in the next five years in global MS drugs market. Among all the product types, Immunomodulators has the highest market share in global Multiple Sclerosis Drugs market.

This report identifies the global pharmaceutical contract manufacturing market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global pharmaceutical contract manufacturing market.

This report segments global Multiple Sclerosis Drugs market on the basis of product type, administration, and regional market as follows:
  • Multiple Sclerosis Drugs Market, By Product Type: Product Type (Immunomodulators, Immunosuppressant, Others) and Others
  • Multiple Sclerosis Drugs Market, By Administration (Inject able, Infused, Oral and Others
  • This report has been further segmented into major regions, which include detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region. The major countries considered under the Asia-Pacific region are India, China, South Korea and Japan. The major countries considered under the European region are Germany, U.K., France, Italy, Spain and Russia. The major countries considered under the North American region are United States, Canada and Mexico

This report identifies all the major companies operating in the Multiple Sclerosis Drugs market. Some of the major companies’ profiles in detail are as follows:
  • Bayer
  • GlaxoSmithKline
  • Teva Pharmaceutical
  • Novartis
  • Merck Serono
1. Multiple Sclerosis Drugs Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Multiple Sclerosis Drugs Market– Market Forces
   4.1. Drivers
      4.1.1. High Unmet need of drugs for treatment of the disease
      4.1.2. increased research in the field of MS to develop innovative therapies
   4.2. Restraints
      4.2.1. Patent expiry of major drugs
      4.2.2. Advancement in biomedical science
   4.3. Opportunities
      4.3.1. Emerging economies
      4.3.2. Increase in adoption of Multiple Sclerosis Drugs
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Multiple Sclerosis Drugs Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Multiple Sclerosis Drugs Market, By Product Type
   6.1. Immunomodulators
   6.2. Immunosuppressant
   6.3. Others
7. Multiple Sclerosis Drugs Market, By Administration
   7.1. Injectable
   7.2. Infused
   7.3. Oral
   7.4. Others
8. Multiple Sclerosis Drugs Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Multiple Sclerosis Drugs – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Bayer
   10.2. GlaxoSmithKline
   10.3. Teva Pharmaceutical
   10.4. Novartis
   10.5. Merck Serono
   10.6. Sanofi
   10.7. Pfizer
   10.8. Abbvie
   10.9. Biogen Idec
   10.10. AB Science
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll